Department of Neurology and Experimental Neurology, Center of Stroke Research Berlin, Charité University Medicine, Charitéplatz 1, Berlin, Germany.
J Cereb Blood Flow Metab. 2013 Sep;33(9):1335-46. doi: 10.1038/jcbfm.2013.93. Epub 2013 Jun 12.
Treatment efficacy for ischemic stroke represents a major challenge. Despite fundamental advances in the understanding of stroke etiology, therapeutic options to improve functional recovery remain limited. However, growing knowledge in the field of epigenetics has dramatically changed our understanding of gene regulation in the last few decades. According to the knowledge gained from animal models, the manipulation of epigenetic players emerges as a highly promising possibility to target diverse neurologic pathologies, including ischemia. By altering transcriptional regulation, epigenetic modifiers can exert influence on all known pathways involved in the complex course of ischemic disease development. Beneficial transcriptional effects range from attenuation of cell death, suppression of inflammatory processes, and enhanced blood flow, to the stimulation of repair mechanisms and increased plasticity. Most striking are the results obtained from pharmacological inhibition of histone deacetylation in animal models of stroke. Multiple studies suggest high remedial qualities even upon late administration of histone deacetylase inhibitors (HDACi). In this review, the role of epigenetic mechanisms, including histone modifications as well as DNA methylation, is discussed in the context of known ischemic pathways of damage, protection, and regeneration.
治疗缺血性脑卒中仍然是一个重大挑战。尽管我们对脑卒中病因学有了基本的认识,但改善功能恢复的治疗选择仍然有限。然而,在过去几十年中,表观遗传学领域的知识增长极大地改变了我们对基因调控的理解。根据从动物模型中获得的知识,表观遗传因子的操纵似乎是一种很有前途的可能性,可以针对多种神经病理学,包括缺血。通过改变转录调控,表观遗传修饰剂可以对涉及缺血性疾病发展的所有已知途径产生影响。有益的转录效应范围从减少细胞死亡、抑制炎症过程和增加血流量,到刺激修复机制和增加可塑性。最引人注目的是在脑卒中动物模型中使用组蛋白去乙酰化酶抑制剂进行药理学抑制所获得的结果。多项研究表明,即使在晚期给予组蛋白去乙酰化酶抑制剂(HDACi),也具有很高的治疗质量。在本文中,将讨论表观遗传机制(包括组蛋白修饰和 DNA 甲基化)在已知的缺血性损伤、保护和再生途径中的作用。